secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXAGEN INC. (XGN)
CIK:        0001274737
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001274737-24-000091
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exagen Q3 revenue $12.5M (-7% YoY); ASP up 26%; net loss improves 37% YTD
-------------------------------------------------------------------------

- Q3 2024 revenue $12.5M, down from $13.4M in Q3 2023, impacted by $1.2M one-time adjustments.
- AVISE CTD trailing twelve-month ASP $404, up 26% from $320 a year ago.
- Net loss first nine months 2024 improved 37% to $11.4M from $18.1M; adj. EBITDA loss improved 42% to $7.6M.
- Cash and equivalents $22.0M at Sept 30; net cash burn $2.5M in Q3.
- Completed validation for new biomarkers, submitted to NY State; appointed Jeff Black as CFO effective Sept 1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1274737/000127473724000091/0001274737-24-000091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1274737/000127473724000091/exdx-20241112.htm
  HTML page:      https://secwatch.observer/filing/0001274737-24-000091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer